Mato, A. R., Roeker, L. E., Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Cheson, B. D., Furman, R. R., Lamanna, N., Tam, C. S., Handunnetti, S., Jacobs, R., Lansigan, F., Bhavsar, E., Barr, P. M., Shadman, M., Skarbnik, A. P., Goy, A., Beach, D. F., Svoboda, J., Pu, J. J., Sehgal, A. R., Zent, C. S., Tuncer, H. H., Schuster, S. J., Pickens, P. V., Shah, N. N., Rhodes, J., Ujjani, C. S., & Nabhan, C. (n.d.). outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial. American journal of hematology, 93(11), 1394–1401. http://access.bl.uk/ark:/81055/vdc_100070819222.0x00003b